---
title: "5-Amino-1MQ"
slug: "5-amino-1mq"
type: "compound"
category: "Body Composition"
url: "https://peptidesciencethailand.com/compounds/5-amino-1mq"
description: "A small molecule that inhibits NNMT, an enzyme linked to fat storage and metabolic slowdown. Body composition research, mechanism, and emerging evidence."
---
# 5-Amino-1MQ

*NNMT Inhibitor, Targeting Cellular Energy Metabolism and Fat Regulation*

**Category:** Body Composition  
**Format:** Capsules  
**Amount:** 50mg x 60 capsules  
**Purity:** >99% (HPLC)

## Overview

5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small molecule research compound that functions as a selective inhibitor of nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme that plays a central regulatory role in cellular energy metabolism, adipogenesis, and epigenetic regulation. Unlike traditional peptides composed of amino acid chains, 5-Amino-1MQ is a quinolinium-based small molecule, included in research compound libraries alongside peptides due to its relevance to metabolic optimization and body composition research. The compound was developed through structure-activity relationship studies aimed at identifying potent and selective NNMT inhibitors.

NNMT catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide (vitamin B3/NAM), producing 1-methylnicotinamide (1-MNA) and S-adenosylhomocysteine (SAH). This reaction sits at a critical metabolic intersection, simultaneously influencing the cellular methylation potential (SAM:SAH ratio), the availability of nicotinamide for NAD+ biosynthesis, and the cellular pool of methyl donors required for epigenetic regulation. NNMT expression is markedly elevated in white adipose tissue of obese individuals, and research has identified NNMT as a key metabolic regulator linking energy sensing to adipocyte differentiation and function.

The primary metabolic consequence of NNMT inhibition by 5-Amino-1MQ is the preservation of intracellular SAM pools. When NNMT activity is high, SAM is consumed to methylate nicotinamide, depleting the methyl donor required for histone and DNA methylation reactions that regulate gene expression. By inhibiting NNMT, 5-Amino-1MQ maintains SAM availability, enabling proper epigenetic regulation of metabolic genes. Research published in the journal Biochemical Pharmacology has demonstrated that NNMT inhibition alters the expression of genes involved in lipogenesis, lipolysis, and mitochondrial bioenergetics in adipocyte cell cultures.

Simultaneously, NNMT inhibition increases the intracellular availability of nicotinamide for NAD+ biosynthesis through the salvage pathway. NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme for mitochondrial oxidative phosphorylation, sirtuin-mediated metabolic regulation, and PARP-dependent DNA repair. Elevated NAD+ concentrations activate SIRT1 and SIRT3 deacetylases, which promote mitochondrial biogenesis, fatty acid oxidation, and oxidative metabolism. This NAD+-boosting mechanism positions NNMT inhibition alongside other NAD+ precursor strategies (NMN, NR) as a complementary approach to enhancing cellular energy metabolism.

Preclinical research has demonstrated significant metabolic effects of NNMT inhibition in animal models of obesity. A landmark study by Neelakantan et al. (2018) published in Biochemical Pharmacology showed that treatment with a selective NNMT inhibitor reduced body weight and white adipose tissue mass in diet-induced obese mice without affecting food intake or lean body mass. The observed fat loss was attributed to increased energy expenditure and enhanced fatty acid oxidation in adipose tissue, mediated through the dual mechanism of SAM preservation and NAD+ elevation.

In adipocyte cell culture studies, 5-Amino-1MQ treatment reduced lipid accumulation during adipogenic differentiation and promoted a metabolic shift from lipid storage toward oxidative metabolism. Gene expression analysis revealed downregulation of lipogenic transcription factors (PPARG, C/EBPalpha) and upregulation of genes involved in mitochondrial fatty acid beta-oxidation and uncoupling protein expression (UCP1), suggesting a potential role in promoting white-to-beige adipocyte conversion, a process known as browning that increases thermogenic energy expenditure.

The selectivity of 5-Amino-1MQ for NNMT over other methyltransferases is an important pharmacological characteristic. The quinolinium scaffold was designed to mimic the nicotinamide substrate and occupy the NNMT active site with high affinity, while the structural differences from substrates of other methyltransferases confer selectivity. This selectivity is important because non-specific methyltransferase inhibition could have widespread epigenetic consequences.

5-Amino-1MQ is cell-permeable and has demonstrated activity in both injectable and oral formulations in preclinical studies. Its small molecular weight and chemical stability distinguish it from peptide-based metabolic compounds that require parenteral administration. The compound does not directly interact with hormonal axes (thyroid, adrenal, gonadal), growth factor receptors, or neurotransmitter systems, which differentiates its metabolic effects from stimulant-based or hormonal approaches to body composition modification.

Ongoing research continues to characterize the dose-response relationship, long-term safety profile, and potential applications of NNMT inhibition beyond adipose tissue metabolism. Studies are exploring NNMT's role in muscle metabolism, hepatic steatosis, and cellular senescence, expanding the potential research applications of compounds in this class. The compound has not yet entered formal human clinical trials, and all published efficacy data derive from preclinical animal models and cell culture experiments.

## Mechanism of Action

### Step 1: NNMT Active Site Binding

5-Amino-1MQ enters cells and binds to the active site of nicotinamide N-methyltransferase (NNMT), competitively inhibiting the enzyme's ability to methylate nicotinamide using S-adenosylmethionine (SAM) as the methyl donor.

### Step 2: SAM Pool Preservation

NNMT inhibition prevents consumption of SAM for nicotinamide methylation, preserving intracellular SAM concentrations. Maintained SAM pools support proper epigenetic regulation through histone and DNA methylation reactions that control metabolic gene expression.

### Step 3: NAD+ Salvage Pathway Enhancement

Increased intracellular nicotinamide availability (no longer consumed by NNMT) feeds the NAD+ salvage pathway through NAMPT-mediated conversion to NMN and subsequent NAD+ synthesis, elevating cellular NAD+ concentrations.

### Step 4: SIRT1/SIRT3 Activation

Elevated NAD+ concentrations activate NAD+-dependent sirtuin deacetylases (SIRT1, SIRT3), which promote mitochondrial biogenesis, fatty acid oxidation gene expression, and the metabolic shift from lipid storage toward oxidative metabolism in adipocytes.

### Step 5: Metabolic Reprogramming of Adipose Tissue

Combined effects of epigenetic regulation (SAM) and sirtuin activation (NAD+) reprogram adipocyte metabolism, downregulating lipogenic transcription factors, upregulating mitochondrial beta-oxidation genes, and promoting thermogenic uncoupling protein expression consistent with white-to-beige adipocyte conversion.

## Researched Benefits

### Enhanced Cellular Energy Expenditure

NNMT inhibition by 5-Amino-1MQ increases cellular energy expenditure through enhanced NAD+-dependent sirtuin activation and mitochondrial fatty acid oxidation. Preclinical studies demonstrate reduced white adipose tissue mass without changes in food intake, consistent with metabolically-driven rather than appetite-mediated body composition effects.

### NAD+ Biosynthesis Support

By preventing NNMT from consuming nicotinamide, 5-Amino-1MQ increases substrate availability for the NAD+ salvage pathway. Elevated NAD+ supports mitochondrial function, sirtuin-mediated metabolic regulation, and PARP-dependent DNA repair, complementing other NAD+ precursor strategies such as NMN supplementation.

### Epigenetic Metabolic Regulation

SAM preservation through NNMT inhibition maintains the cellular methylation potential required for proper epigenetic regulation of metabolic genes. This mechanism influences the expression of transcription factors governing adipogenesis, lipogenesis, and mitochondrial biogenesis through histone modification pathways.

### Non-Hormonal, Non-Stimulant Mechanism

5-Amino-1MQ operates through enzyme inhibition at the metabolic level without directly engaging hormonal axes, growth factor receptors, or adrenergic neurotransmitter systems. This mechanism distinguishes it from stimulant-based or hormonal approaches to metabolic modulation, offering a distinct pharmacological profile.

## Dosage & Administration

| Parameter | Detail |
| --- | --- |
| Protocol | 50-150mg per day orally, typically divided into 1-2 doses |
| Route | Oral administration (capsule) or subcutaneous injection |
| Duration | Research protocols typically span 4-8 weeks |
| Cycle Notes | Common research protocols incorporate 4-8 week administration periods followed by equal rest periods. Due to the compound's enzyme-inhibitory mechanism, effects are expected to reverse upon discontinuation as NNMT activity normalizes. |
| Reconstitution | For oral administration, capsules are taken with or without food. For injectable preparation, reconstitute lyophilized powder with bacteriostatic water according to concentration requirements. Store reconstituted solution at 2-8C. |

> **Specialist note:** A your specialist will evaluate metabolic health markers, liver function, renal function, and current medications before initiating a 5-Amino-1MQ protocol. As the compound modulates fundamental metabolic enzyme activity and NAD+ homeostasis, individuals with metabolic disorders, liver conditions, or those taking medications affecting methylation pathways require careful assessment.

## Compound Reference Data

| Property | Value |
| --- | --- |
| Format | Capsules or Lyophilized Powder |
| Amount | 50mg x 60 capsules or 500mg powder |
| Purity | >99% |
| Purity Method | HPLC (High-Performance Liquid Chromatography) |
| Composition | 5-Amino-1-methylquinolinium chloride (small molecule, not a peptide) |
| Molecular Weight | 174.63 g/mol (free base) |
| Storage | Store at room temperature in a cool, dry place protected from light and moisture. Stable at ambient conditions. |
| Appearance | Off-white to pale yellow crystalline powder |

## Medical Guidance

5-Amino-1MQ is a small molecule enzyme inhibitor, not a peptide, that modulates fundamental cellular metabolic pathways including NAD+ homeostasis and SAM-dependent methylation reactions. These pathways influence diverse cellular processes beyond fat metabolism. A specialist should evaluate liver function, metabolic markers, and medication interactions before initiating a protocol, with particular attention to compounds or conditions affecting methylation metabolism or NAD+ homeostasis.

## Frequently Asked Questions

### Is 5-Amino-1MQ a peptide?

No. 5-Amino-1MQ is a small molecule quinolinium compound, not a peptide. It is included in research compound libraries alongside peptides because of its relevance to metabolic optimization research and body composition studies. Its mechanism of action (NNMT enzyme inhibition) is distinct from peptide-receptor interactions, and its small molecular weight enables oral bioavailability unlike most peptide compounds.

### What is NNMT and why is it a research target?

Nicotinamide N-methyltransferase (NNMT) is a cytosolic enzyme that methylates nicotinamide using SAM as a methyl donor. It has become a significant research target because NNMT expression is markedly elevated in white adipose tissue of obese individuals, and its activity depletes both SAM (needed for epigenetic regulation) and nicotinamide (needed for NAD+ biosynthesis). Inhibiting NNMT simultaneously preserves these two critical metabolic substrates.

### How does 5-Amino-1MQ relate to NAD+ and NMN research?

5-Amino-1MQ and NMN both increase cellular NAD+ levels, but through different mechanisms. NMN is a direct NAD+ precursor that feeds into the salvage pathway as a substrate. 5-Amino-1MQ inhibits NNMT from consuming nicotinamide, thereby increasing nicotinamide availability for conversion to NMN and subsequently NAD+ through the same salvage pathway. These approaches are mechanistically complementary.

### Does 5-Amino-1MQ affect appetite or act as a stimulant?

Based on preclinical research, 5-Amino-1MQ does not appear to affect food intake or function as a central nervous system stimulant. Its metabolic effects are mediated through enzyme inhibition at the cellular level, influencing energy expenditure and fat metabolism through NAD+ elevation and epigenetic regulation rather than appetite suppression or adrenergic stimulation. This mechanism is distinct from stimulant-based or appetite-suppressing weight management approaches.

### Is specialist supervision needed for 5-Amino-1MQ?

Yes. Although 5-Amino-1MQ has a relatively targeted mechanism, it modulates fundamental metabolic enzymes that influence NAD+ homeostasis, cellular methylation, and energy metabolism. A specialist should evaluate liver function, metabolic health markers, and potential medication interactions before initiating a protocol. The compound remains in preclinical research stages, making informed medical oversight essential.

## Related Compounds

- /compounds/aod-9604
- /compounds/tesamorelin
- /compounds/mots-c